Evidence map›Paper›PMID 31528087›Full record

ReviewWorld journal of gastroenterology2019

New Era: Endoscopic treatment options in obesity-a paradigm shift.

Jason Glass, Ahson Chaudhry, Muhammad S Zeeshan, Zeeshan Ramzan

Registry-linked trialAbstract readReview
In one paragraph

Review in World journal of gastroenterology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05420506 (Treatment of Obesity Without Surgical Intervention by Reversible Reduction of the Small Intestinal Absorption Area), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05420506 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Treatment of Obesity Without Surgical Intervention by Reversible Reduction of the Small Intestinal Absorption Area

TypeinterventionalSponsorYeditepe UniversityRan2022 to 2024Enrolled20ConditionsMorbid ObesityArmsNROT1
3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Gaps in obesity management in the UAE and the role of bariatric endoscopy.Frontiers in gastroenterology (Lausanne, Switzerland) · 2023
    Review
  17. [Intragastric balloon for weight reduction: rationale, benefits, risks and indications].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  18. Review
  19. Endoscopic sleeve gastroplasty requiring emergent partial gastrectomy.Proceedings (Baylor University. Medical Center) · 2020
    Article
  20. Training in bariatric and metabolic endoscopy.Therapeutic advances in gastrointestinal endoscopy
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jason GlassDepartment of Digestive and Liver Diseases, University of Texas Southwestern Medical Center, Dallas, TX 75390, United States.
Ahson ChaudhryDivision of Gastroenterology and Hepatology, Department of Medicine, Dallas VA Medical Center, VA North Texas Health Care System, Dallas, TX 75216, United States.
Muhammad S ZeeshanDivision of Gastroenterology and Hepatology, Department of Medicine, Dallas VA Medical Center, VA North Texas Health Care System, Dallas, TX 75216, United States.
Zeeshan RamzanDivision of Gastroenterology and Hepatology, Department of Medicine, Dallas VA Medical Center, VA North Texas Health Care System, Dallas, TX 75216, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The prevalence of obesity continues to rise, and along with it comes a multitude of health-related consequences. The healthcare community has consistently struggled with providing treatment options to obese patients, in part due to the reluctance of patients in pursuing the more effective (yet invasive) surgical approaches such as sleeve gastrectomy and Rou-en-Y gastric bypass. On the other hand, the less invasive approach such as lifestyle/behavioral interventions and pharmacotherapy (Orlistat, Phenteramine, Phentermine/Topiramate, Locaserin, Naltrexon/Buproprion, and Liraglutide) have very limited efficacy, especially in the morbidly obese patients. Despite our best efforts, the epidemic of obesity continues to rise and pose enormous costs on our healthcare system and society. Bariatric endoscopy is an evolving field generated to combat this epidemic through minimally invasive techniques. These procedures can be performed in an ambulatory setting, are potentially reversible, repeatable, and pose less complications than their invasive surgical counterparts. These modalities are designed to alter gut metabolism by means of space occupation, malabsorption, or restriction. In this review we will discuss different bariatric endoscopic options (such as intragastric balloons, endoscopic sleeve gastroplasty, endoscopic aspiration therapies and gastrointestinal bypass sleeves), their advantages and disadvantages, and suggest a new paradigm where providers may start incorporating this modality in their treatment approach for obese patients.

Indexed as

Bariatric SurgeryEndoscopyGastroenterologyHumansObesity, MorbidPrevalenceTreatment OutcomeWeight LossAspireAssistBariatric endoscopyBariatric medicineBariatricsEndoscopic sleeve gastroplastyIntragastric balloonObesity

Identifiers

PMID31528087
PMCPMC6718037

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.